Lantern Pharma Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Lantern Pharma Inc. (LTRN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $37.35 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $18.63K, a 61.95% decline year-over-year.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $18.73K, a 60.81% decline year-over-year.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $43.00K, a 7.82% decline year-over-year.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $50.15K, a 15.37% increase year-over-year.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $189.90K, a 9.63% increase from fiscal 2024.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $173.21K, a 8.10% increase from fiscal 2023.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $160.23K, a 15.89% increase from fiscal 2022.
- Lantern Pharma Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $138.26K, a 56.17% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $37.35K 10-Q · filed 2026-08-14 | $80.36K derived: sum of 3 quarters · filed 2026-08-14 | $130.50K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $18.73K 10-Q · filed 2026-05-15 | $61.73K derived: sum of 2 quarters · filed 2026-05-15 | $111.88K derived: sum of 3 quarters · filed 2026-05-15 | $160.84K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $93.15K derived: sum of 2 quarters · filed 2026-03-30 | $142.11K derived: sum of 3 quarters · filed 2026-03-30 | $189.90K 10-K · filed 2026-03-30 |
| 2025-09-30 | $50.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $99.11K derived: sum of 2 quarters · filed 2025-11-12 | $146.90K 10-Q · filed 2025-11-12 | $193.54K derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-06-30 | $48.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $96.75K 10-Q · filed 2025-08-13 | $143.40K derived: sum of 3 quarters · filed 2026-03-30 | $186.86K derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-03-31 | $47.79K 10-Q · filed 2025-05-15 | $94.44K derived: sum of 2 quarters · filed 2026-03-30 | $137.91K derived: sum of 3 quarters · filed 2026-03-30 | $179.92K derived: sum of 4 quarters · filed 2026-03-30 |
| 2024-12-31 | $46.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $90.12K derived: sum of 2 quarters · filed 2026-03-30 | $132.13K derived: sum of 3 quarters · filed 2026-03-30 | $173.21K 10-K · filed 2026-03-30 |
| 2024-09-30 | $43.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $85.48K derived: sum of 2 quarters · filed 2024-11-07 | $126.56K 10-Q · filed 2024-11-07 | $166.90K derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-06-30 | $42.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $83.09K 10-Q · filed 2024-08-08 | $123.43K derived: sum of 3 quarters · filed 2025-03-27 | $163.05K derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-03-31 | $41.08K 10-Q · filed 2024-05-09 | $81.43K derived: sum of 2 quarters · filed 2025-03-27 | $121.04K derived: sum of 3 quarters · filed 2025-03-27 | $161.29K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $40.34K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $79.96K derived: sum of 2 quarters · filed 2025-03-27 | $120.20K derived: sum of 3 quarters · filed 2025-03-27 | $160.23K 10-K · filed 2025-03-27 |
| 2023-09-30 | $39.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $79.86K derived: sum of 2 quarters · filed 2023-11-08 | $119.89K 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $40.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $80.27K 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $40.02K 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $138.26K 10-K · filed 2024-03-18 | |||
| 2021-12-31 | $88.53K 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |